Literature DB >> 27453698

Appropriate Use of Vancomycin in NICU Despite Free-for-All Policy.

Benjamin M Hammer1, Allison B Lardieri2, Jill A Morgan2.   

Abstract

OBJECTIVES: Because of increases in antimicrobial resistance, the use of vancomycin in late-onset sepsis has come under scrutiny. The primary outcome of this study was to determine if vancomycin for the treatment of late-onset sepsis in the neonatal intensive care unit (NICU) was being discontinued within 72 hours according to the existing protocol. Secondary outcomes included the appropriateness of therapeutic drug monitoring associated with vancomycin, and renal dysfunction associated with the use of vancomycin in the NICU outside of the 72-hour policy.
METHODS: A retrospective chart review was completed for patients in the NICU who received vancomycin for the treatment of late-onset sepsis between the dates of January 1, 2014, and July 1, 2014.
RESULTS: There were 125 vancomycin treatment courses, of which 97 were included. Appropriate use of vancomycin, per policy, occurred in a total of 87 of 97 courses (89.6%). Therapeutic drug monitoring was evaluated by the number of appropriate troughs, determined using renal function and previous trough concentrations. There was not a statistically significant difference in the number of inappropriate troughs drawn between those that were continued on vancomycin appropriately (n = 17 courses; 4 of 44 inappropriate troughs) versus inappropriately (n = 10 courses; 1 of 22 inappropriate troughs; p = 0.66), despite the large number of troughs drawn. Adverse renal outcomes were not statistically significant in patients continued inappropriately on vancomycin (p = 1.0).
CONCLUSIONS: Vancomycin use in the NICU for late-onset sepsis is appropriate per the existing antibiotic policy. Therapeutic drug monitoring could be improved, and adverse renal outcomes due to inappropriate continuation of vancomycin are rare.

Entities:  

Keywords:  antibiotics; late-onset sepsis; newborn intensive care units; serum concentrations; therapeutic drug monitoring; vancomycin

Year:  2016        PMID: 27453698      PMCID: PMC4956328          DOI: 10.5863/1551-6776-21.3.207

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  8 in total

1.  Effectiveness of a guideline to reduce vancomycin use in the neonatal intensive care unit.

Authors:  Chia-Hua Chiu; Ian C Michelow; Jonathan Cronin; Steven A Ringer; Timothy G Ferris; Karen M Puopolo
Journal:  Pediatr Infect Dis J       Date:  2011-04       Impact factor: 2.129

2.  Trends in sepsis-related neonatal mortality in the United States, 1985-1998.

Authors:  Susan L Lukacs; Kenneth C Schoendorf; Anne Schuchat
Journal:  Pediatr Infect Dis J       Date:  2004-07       Impact factor: 2.129

3.  Antibiotic use in neonatal intensive care units and adherence with Centers for Disease Control and Prevention 12 Step Campaign to Prevent Antimicrobial Resistance.

Authors:  Sameer J Patel; Adebayo Oshodi; Priya Prasad; Patricia Delamora; Elaine Larson; Theoklis Zaoutis; David A Paul; Lisa Saiman
Journal:  Pediatr Infect Dis J       Date:  2009-12       Impact factor: 2.129

4.  Prospective surveillance of antibiotic use in the neonatal intensive care unit: results from the SCOUT study.

Authors:  Joseph B Cantey; Phillip S Wozniak; Pablo J Sánchez
Journal:  Pediatr Infect Dis J       Date:  2015-03       Impact factor: 2.129

Review 5.  How to optimize the evaluation and use of antibiotics in neonates.

Authors:  Johannes N van den Anker
Journal:  Early Hum Dev       Date:  2014-03       Impact factor: 2.079

Review 6.  Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration.

Authors:  Evelyne Jacqz-Aigrain; Wei Zhao; Mike Sharland; John N van den Anker
Journal:  Semin Fetal Neonatal Med       Date:  2012-11-06       Impact factor: 3.926

7.  Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin: a non-inferiority, randomized, controlled trial.

Authors:  José M Ceriani Cernadas; Silvia Fernández Jonusas; Maritza Márquez; Armando Garsd; Gonzalo Mariani
Journal:  Arch Argent Pediatr       Date:  2014-08       Impact factor: 0.694

8.  No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants.

Authors:  Jessica E Ericson; Joshua Thaden; Heather R Cross; Reese H Clark; Vance G Fowler; Daniel K Benjamin; Michael Cohen-Wolkowiez; Christoph P Hornik; P Brian Smith
Journal:  Pediatr Infect Dis J       Date:  2015-04       Impact factor: 3.806

  8 in total
  2 in total

1.  Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations.

Authors:  Joaquim F Monteiro; Siomara R Hahn; Jorge Gonçalves; Paula Fresco
Journal:  Pharmacol Res Perspect       Date:  2018-07

2.  Vancomycin-lock therapy for prevention of catheter-related bloodstream infection in very low body weight infants.

Authors:  Hong Liang; Lian Zhang; Xiaoping Guo; Li Sun
Journal:  BMC Pediatr       Date:  2021-01-04       Impact factor: 2.125

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.